News | February 17, 2022
Asahi Kasei to build new filter assembly plant in Japan
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
Apexxnar is the first pneumococcal conjugate vaccine to help protect adults ages 18 years and older against 20 serotypes responsible for the majority of invasive disease and pneumococcal pneumonia
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
Dr. Peter Houghton will lead the research collaboration for GCCRI and is widely regarded as a leading expert in pediatric cancer research and in the development of novel approaches to treating childhood cancers
Through this acquisition, Ayu Health will add 1000 beds to provide localised primary and tertiary medical care for citizens of Jaipur
The entire integration and transition of the brands is expected to be completed by March 2022
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
The recommendation has been sent to the DCGI for approval
Subscribe To Our Newsletter & Stay Updated
